Free · no account · quoted from the filing

What changed in CI's 10-Q

Source: 10-Q filed 2026-04-30 · compared against 10-Q 2025-10-30. Every passage below is quoted verbatim from the filing itself.

Revenue mix (divestiture impact)

This filing

Pharmacy revenues $ 54,037 $ 48,633 11 % ... Premiums 9,812 12,736 (23)

Net income

This filing

SHAREHOLDERS' NET INCOME $ 1,654 $ 1,323

Strategic costs

This filing

Strategic optimization program $ 380 $ 290 $ 215 $ 163

Balance sheet leverage

This filing

Long-term debt $ 29,371 $ 30,871

Accounts receivable

This filing

Accounts receivable, net $ 26,607 $ 28,768

Guarantee liability

This filing

This guarantee liability was $ 2.0 billion as of March 31, 2026 and $ 1.8 billion as of December 31, 2025.

Share count

This filing

264,532,404 shares of the issuer's Common Stock were outstanding

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.